February, 2003
© 2000 Scott S. Emerson, M.D., Ph.D.
Session
4:
66
Case Study 1: Idarubicin in AML
Sensitivity analysis
(25, 45, 65, 90)
Best Case
Worst Case
·
Level
.958
.868
·
P value
.008
.016
·
Estimate
.184
.175
·
95% CI
(.034,.325)
(.017,.348)